We are live on ! Find out more
SRPT icon

Sarepta Therapeutics
SRPT

148 hedge funds and large institutions have $661M invested in Sarepta Therapeutics in 2016 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

44% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 34

12% more funds holding

Funds holding: 132 → 148 (+16)

3% less capital invested

Capital invested by funds: $680M → $661M (-$19.4M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

38% less call options, than puts

Call options by funds: $270M | Put options by funds: $436M

Holders
148
Holders Change
+16
Holders Change %
+12.12%
% of All Funds
3.95%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
36
Increased
49
Reduced
34
Closed
20
Calls
$270M
Puts
$436M
Net Calls
-$165M
Net Calls Change
-$167M

Top Buyers

1
Jennison Associates
Jennison Associates
New York
+$19.4M
2
State Street
State Street
Massachusetts
+$11.6M
3
Morgan Stanley
Morgan Stanley
New York
+$9.67M
4
Group One Trading
Group One Trading
Illinois
+$9.41M
5
MP
Mangrove Partners
Connecticut
+$9.12M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$25.1M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$21.2M
3
TCP
Tourbillon Capital Partners
New York
-$15.7M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$13.9M
5
PC
PointState Capital
New York
-$13.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
76
Citigroup
New York
$619K -$940K -50,735 -61%
BBHC
77
Brown Brothers Harriman & Co
New York
$610K – – –
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
$606K – – –
DCM
79
Dialectic Capital Management
Connecticut
$572K +$556K +30,000 New
UCFA
80
United Capital Financial Advisors
Texas
$571K – – –
Manulife (Manufacturers Life Insurance)
81
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$558K -$8.24K -445 -1%
NFA
82
Nationwide Fund Advisors
Ohio
$535K -$12.5K -677 -2%
CIBC World Market
83
CIBC World Market
Ontario, Canada
$529K -$25.7K -1,390 -5%
EA
84
Emerald Acquisition
Washington
$496K +$482K +26,004 New
SEC
85
Seven Eight Capital
New York
$483K +$469K +25,302 New
AC
86
Amici Capital
New York
$477K – – –
EEG
87
E.E. Geduld
$477K +$463K +25,000 New
AIG
88
American International Group
New York
$469K -$177K -9,553 -28%
DekaBank Deutsche Girozentrale
89
DekaBank Deutsche Girozentrale
Germany
$462K +$97.2K +5,250 +27%
Stifel Financial
90
Stifel Financial
Missouri
$441K +$21.8K +1,178 +5%
NPC
91
National Planning Corporation
California
$410K +$44K +2,375 +17%
OC
92
Oppenheimer & Co
New York
$385K +$374K +20,213 New
Jacobs Levy Equity Management
93
Jacobs Levy Equity Management
New Jersey
$349K +$339K +18,300 New
VOYA Investment Management
94
VOYA Investment Management
Georgia
$348K – – –
BlackRock
95
BlackRock
New York
$347K +$281K +15,160 +499%
GGHC
96
Gilder Gagnon Howe & Co
New York
$343K -$759 -41 -0.2%
HCA
97
Harbour Capital Advisors
Virginia
$335K – – –
QOP
98
Quinn Opportunity Partners
Virginia
$334K +$324K +17,500 New
Commonwealth Equity Services
99
Commonwealth Equity Services
Massachusetts
$302K +$293K +15,828 New
RJA
100
Raymond James & Associates
Florida
$289K +$42.6K +2,300 +18%
2 3
4
5 6

SRPT Hedge Fund Activity: Q2 2016 in Review

148 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2016, worth a combined $661M — down 2.9% from $680M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new SRPT positions and 20 closed out — a net gain of 16 holders — while 49 added to existing stakes and 34 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $19.4M. The largest seller was Citadel Advisors, cutting an estimated $25.1M.

  • 148 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2016, up from 132 in Q1 2016.
  • Funds reported $661M of Sarepta Therapeutics stock for Q2 2016, down 2.9% quarter-over-quarter.
  • 36 funds opened new Sarepta Therapeutics positions in Q2 2016 and 20 closed out, a net change of +16 holders.
  • The largest Sarepta Therapeutics buyer in Q2 2016 was Jennison Associates, an estimated $19.4M added.
  • The largest Sarepta Therapeutics seller in Q2 2016 was Citadel Advisors, an estimated $25.1M sold.

Based on aggregated 13F filings for Q2 2016.